Your new post is loading...
After the Brexit storm, the U.K. bioindustry may find itself becalmed, unable to commercialize its cellular therapeutics know-how. Seize the fiscal and regulatory oars!
|
Scooped by BigField GEG Tech |
Scoop.it!
No comment yet.
Sign up to comment
The U.K. has ambitions to become the third largest global life science cluster by 2025,” stated Nick Gardiner, COO of the BioIndustry Association (BIA) at the recent bioProcessUK Conference in Newcastle. This goal could be achieved, attendees suggested, by various means. For example, many attendees agreed that the U.K. could attract and retain manufacturers of advanced therapy medicinal products (ATMPs). However, producing ATMPs such as cell and gene therapies is not an easy business. It requires investments in infrastructure, skilled people, and processes for efficient and profitable manufacturing.